Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; water for injections; phenol; sodium hydroxide; glycerol; metacresol; protamine sulfate; hydrochloric acid; dibasic sodium phosphate heptahydrate - for the treatment of insulin dependent diabetic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; glycerol; metacresol; zinc oxide; phenol; dibasic sodium phosphate heptahydrate; protamine sulfate; hydrochloric acid; water for injections - this product accepted for registration as 'currently supplied' at the time of commencement of the act. humulin is indicated for the treatment of insulin-dependent diabetic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

United States - English - NLM (National Library of Medicine)

stat rx usa llc - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - solution for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israel - English - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israel - English - Ministry of Health

eli lilly israel ltd, israel - insulin lispro - solution for injection - insulin lispro 100 u/ml - insulin lispro - insulin lispro - humalog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog is also indicated for the initial stabilization of diabetes mellitus.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - insulin lispro - solution for injection - insulin lispro 100 u/ml - insulin lispro - insulin lispro - humalog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog is also indicated for the initial stabilization of diabetes mellitus.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis